AN2 THERAPEUTICS INC (ANTX) Stock News

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

12 Health Care Stocks Moving In Thursday's After-Market Session

Mentions: CYTK EXAS ONMD SSII ...

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

Citizens And 2 Other Penny Stocks Insiders Are Buying

Mentions: CIA RPHM

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024

ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AN2 Therapeutics (NASDAQ:ANTX) just reported results for the second quarter of ...

Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?

AN2 Therapeutics stock is down on Friday after ANTX investors learned of the company terminating its EBO-301 Phase 2/3 clinical trial.

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AN2 Therapeutics (NASDAQ:ANTX) just reported results for the first quarter of 2...

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024

ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AN2 Therapeutics (NASDAQ:ANTX) just reported results for the fourth quarter of ...

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023

ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!

Mentions: AVD BBLG BW CMND ...

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...